I. N. van Schaik

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

G. L. Masson, D. Yarnitsky, S. Muley, 2018, The Lancet Neurology.